These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6320589)

  • 21. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin.
    Fuxe K; Von Euler G; Agnati LF; Merlo Pich E; O'Connor WT; Tanganelli S; Li XM; Tinner B; Cintra A; Carani C
    Ann N Y Acad Sci; 1992; 668():186-204. PubMed ID: 1361113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the inhibitory effect of adrenocorticotropin/melanocyte-stimulating hormone-like peptides on the binding of dopamine receptor ligands to the dopamine D2 receptor in vitro.
    Florijn WJ; De Boer T; Tonnaer JA; Versteeg DH
    J Pharmacol Exp Ther; 1992 Nov; 263(2):787-92. PubMed ID: 1331413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of [125I]-N-(p-aminophenethyl)spiroperidol to the D-2 dopamine receptor in the neurointermediate lobe of the rat pituitary gland: a thermodynamic study.
    Agui T; Amlaiky N; Caron MG; Kebabian JW
    Mol Pharmacol; 1988 Feb; 33(2):163-9. PubMed ID: 2963208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors.
    Creese I; Padgett L; Fazzini E; Lopez F
    Eur J Pharmacol; 1979 Jul; 56(4):411-2. PubMed ID: 477735
    [No Abstract]   [Full Text] [Related]  

  • 25. Dopaminergic 2-aminotetralins: affinities for dopamine D2-receptors, molecular structures, and conformational preferences.
    Johansson AM; Karlén A; Grol CJ; Sundell S; Kenne L; Hacksell U
    Mol Pharmacol; 1986 Sep; 30(3):258-69. PubMed ID: 2943981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perinatal asphyxia induces long-term changes in dopamine D1, D2, and D3 receptor binding in the rat brain.
    Chen Y; Hillefors-Berglund M; Herrera-Marschitz M; Bjelke B; Gross J; Andersson K; von Euler G
    Exp Neurol; 1997 Jul; 146(1):74-80. PubMed ID: 9225740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective labelling of different dopamine receptors by a new agonist 3H-ligand: 3H-N-propylnorapomorphine.
    Titeler M; Seeman P
    Eur J Pharmacol; 1979 Jun; 56(3):291-2. PubMed ID: 477726
    [No Abstract]   [Full Text] [Related]  

  • 28. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
    Gao YG; Baldessarini RJ; Kula NS; Neumeyer JL
    J Med Chem; 1990 Jun; 33(6):1800-5. PubMed ID: 1971309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved high-affinity binding of 3H-apomorphine with a subcellular membrane fraction of mammalian brain tissue.
    Arana GW; Baldessarini RJ; Herschel M; Fava M
    Life Sci; 1981 Jul; 29(2):121-33. PubMed ID: 6270486
    [No Abstract]   [Full Text] [Related]  

  • 30. A mosaic-like distribution of dopamine receptors in rat neostriatum and its relationship to striosomes.
    Loopuijt LD; Sebens JB; Korf J
    Brain Res; 1987 Mar; 405(2):405-8. PubMed ID: 3567618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation.
    Jolicoeur FB; De Michele G; Barbeau A; St-Pierre S
    Neurosci Biobehav Rev; 1983; 7(3):385-90. PubMed ID: 6322065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible and irreversible components of [(3)H]-N-propylnorapomorphine interaction with rat striatal membranes.
    Lepiku M; Järv J; Fuxe K; Rinken A
    Neurosci Lett; 2002 Jun; 325(2):111-4. PubMed ID: 12044634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor affinities of aporphine enantiomers in rat brain tissue.
    Baldessarini RJ; Kula NS; Zong R; Neumeyer JL
    Eur J Pharmacol; 1994 Mar; 254(1-2):199-203. PubMed ID: 7911429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of specific binding of several putative neuro-transmitters to human fibroblasts.
    Berrettini WH; Nadi NS; Gershon ES
    J Recept Res; 1983; 3(3):409-21. PubMed ID: 6137566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of N-n-propylnorapomorphine in plasma and tissue by capillary gas chromatography--electron-capture detection.
    Maksoud HM; Kuttab SH; Neumeyer JL; Vouros P
    J Chromatogr; 1983 May; 274():149-59. PubMed ID: 6874818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-related changes in local glucose utilization in the brain.
    Smith CB; Sokoloff L
    Exp Brain Res; 1982; Suppl 5():76-85. PubMed ID: 7151924
    [No Abstract]   [Full Text] [Related]  

  • 37. Opiate receptor binding in rhesus monkey brain: association with limbic structures.
    LaMotte CC; Snowman A; Pert CB; Synder SH
    Brain Res; 1978 Oct; 155(2):374-9. PubMed ID: 210898
    [No Abstract]   [Full Text] [Related]  

  • 38. An hypothesis of the molecular structure of the dopamine receptor.
    Smythies JR
    Med Hypotheses; 1981 Dec; 7(12):1449-56. PubMed ID: 7334949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease of limbic dopamine D2 receptors and ethanol preference.
    Gallant DM
    Alcohol Clin Exp Res; 1992 Dec; 16(6):1174. PubMed ID: 1471774
    [No Abstract]   [Full Text] [Related]  

  • 40. The manifold actions of neurotensin, a trophotropic agent.
    Prange AJ
    Ann N Y Acad Sci; 1992; 668():298-306. PubMed ID: 1463272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.